Lipids & metabolic liver disease
Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease
Authors' conclusion
In patients with AF, NAFLD is associated with a higher 1-year risk of adverse events, with the risk of adverse events progressively increasing from noncirrhotic to cirrhotic and from nonthrombocytopenic to thrombocytopenic patients. NOACs were associated with a better effectiveness and safety profile compared to warfarin.
Study context
- Population
- Patients with atrial fibrillation (AF) on oral anticoagulation (OAC), TriNetX health research network
- Participants
- 22,636 vs 391,014
- Exposure
- AF with nonalcoholic fatty liver disease (NAFLD) vs AF without liver disease, on oral anticoagulation
- AF-NAFLDn = 22,636
- AF without liver diseasen = 391,014reference
- Outcome
- (1) Composite cardiovascular outcome (all-cause death, MI, stroke, cardiac arrest, PE) and (2) composite hemorrhagic outcome (intracranial hemorrhage and gastrointestinal bleeding)
- Follow-up
- 1 year
Methodological detailshealth research network (TriNetX), propensity score matching
- Health research network (TriNetX)
- Propensity score matching
Main finding
As reported in the abstract
AF-NAFLD vs AF without liver diseaseHazard ratio (95% CI)
Composite cardiovascular outcome
1.54(1.47–1.61)
Composite hemorrhagic outcome
1.56(1.42–1.72)
Observational data: associations, not effects.
Further findings
Cirrhosis and thrombocytopenia (sensitivity analyses)
- Cirrhotic and thrombocytopenic patients with AF-NAFLD showed the highest risks
Type of OAC in AF-NAFLD: warfarin vs NOACs (sensitivity analysis)
- Warfarin associated with a higher risk of cardiovascular and hemorrhagic outcomes than NOACs
Original publication
Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. Published 12 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →